ArticleNorthern clinics of Istanbul2026
Impact of body mass index on progression-free survival and endocrine immune-related adverse events in advanced NSCLC patients treated with nivolumab: A retrospective cohort study.
Sila Oksuz et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.